Application of rhizoma bletillae polysaccharide in preparation of submucosal injection for treatment under digestive endoscopy

By using submucosal injection prepared in digestive endoscopic treatment with white and polysaccharides, the problems of short maintenance time and safety hazards of submucosal injections in the prior art are solved, and longer uplift maintenance and higher Treatment efficiency reduces costs and complication risks.

CN118903184APending Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF TCM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411257683.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing submucosal injections maintain a short bulge during digestive endoscopic treatment, and some components have safety hazards and high cost problems.

Method used

White and polysaccharides are used as the main components of submucosal injection, prepared by specific extraction and treatment methods, added to normal saline to prepare it into submucosal injection, combined with methylene blue or indigo carume as dyeing agent, and used for EMR or ESD surgery .

Benefits of technology

It effectively extends the time of submucosal bulge, improves the efficiency of endoscopic surgery, reduces the incidence of complications, is low cost, is simple to operate, and is safe.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903184A_ABST
    Figure CN118903184A_ABST
Patent Text Reader

Abstract

The invention relates to an application of rhizoma bletillae polysaccharide in preparation of submucosal injection for treatment under a digestive endoscopy, which can effectively solve the problem that the upheaval maintaining time is short when the existing submucosal injection is injected into the submucosa, and adopts the technical scheme that the application of the rhizoma bletillae polysaccharide in preparation of the submucosal injection for treatment under the digestive endoscopy is used for solving the problem that the upheaval maintaining time is short when the existing submucosal injection is injected into the submucosa. A preparation method of the injection comprises the step of adding 0.25-0.5 g of rhizoma bletillae polysaccharide and 0.1 g of methylene blue or indigo carmine into 40 ml of normal saline to prepare the submucosal injection. The rhizoma bletillae polysaccharide is low in cost, simple in production process, simple and convenient to use under an endoscope, long in submucosal upheaval maintaining time when being added into the submucosal injection for use, simple to operate, good in using effect and high in practicability, and the application prospect is broad. The bletilla striata polysaccharide injection is an innovation of submucosal injection in treatment under a digestive endoscope, and a new application of the bletilla striata polysaccharide is developed.
Need to check novelty before this filing date? Find Prior Art

Description

1. Technical Field

[0001] The invention relates to the field of digestive endoscopy, in particular to the use of Bletilla striata polysaccharide in the preparation of submucosal injection for digestive endoscopic treatment. 2. Background Technology

[0002] The main purpose of gastroenteroscopy in clinical practice is to diagnose and endoscopically treat gastrointestinal lesions. Common endoscopic resection methods include biopsy forceps removal, high-frequency electric snare resection, argon plasma scalpel therapy (APC), endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD). Among them, submucosal injection and the treatment of large wounds after resection are the key points of EMR and ESD, and are also the current research hotspots.

[0003] An ideal submucosal injection solution usually needs to have the following characteristics: ① It can form a thick submucosal fluid pad to maintain the bulge; ② The submucosal bulge can be maintained long enough without the need for frequent injections; ③ It is cheap and easy to obtain, safe and easy to store, and convenient for injection; ④ It can reduce the incidence of complications such as bleeding or perforation; ⑤ It can completely remove the lesion to obtain accurate pathological results.

[0004] At present, the more classic and commonly used submucosal injection solutions include normal saline, glycerol fructose, hypertonic glucose solution, hyaluronic acid, etc. Among them, normal saline is the most commonly used because it is safe and cheap, but it is easily absorbed by the surrounding tissues and cannot be maintained for a sufficient time, so multiple injections are required. Glycerol fructose is a hypertonic solution, which is a mixture of 10% glycerol and 5% fructose in saline. Because of its hypertonic properties, it can maintain the bulge longer than normal saline. However, glycerol fructose will be ionized and produce smoke due to the use of electrocoagulation or electroresection during ESD surgery, which will affect the surgical field of view and may bring some safety hazards. Hypertonic glucose solution also has a better effect on maintaining the bulge than normal saline due to its hypertonicity, but studies have shown that the concentration of glucose solution exceeds 20% will cause tissue damage, so that accurate pathological results cannot be obtained after surgery, and the assessment of lesion depth and cutting edge conditions will produce errors, and it will also affect the healing of postoperative tissues. Hyaluronic acid is an ideal submucosal injection solution. It has high viscosity, good water storage capacity, is safe and non-toxic, and can maintain the elevation for a long time. Its disadvantages are that it is relatively expensive and may stimulate the growth of residual tumor cells.

[0005] In recent years, some new submucosal injection solutions have emerged, such as sodium alginate, hydroxypropyl methylcellulose, sodium hydroxyethyl starch solution, fibrinogen mixture, carboxymethyl cellulose (sodium), Eleview, ORISE gel, etc. Although these new submucosal injection solutions have their own advantages, there is no consensus on the application of submucosal injection solutions in ESD at home and abroad. However, it is generally recognized that some adjuvants can be added to the submucosal injection solution to reduce the occurrence of related complications. The most famous and widely used are diluted adrenaline solution and dyes such as diluted indigo carmine or methylene blue. The submucosal injection solution currently used in my country is a combination of a small amount of adrenaline and indigo carmine in physiological saline. The addition of adrenaline can reduce bleeding, and the dyeing effect of indigo carmine can identify the range of peeling and control the depth of peeling. Clinical practice has confirmed that it can basically meet the needs of ESD treatment. However, adrenaline may cause reactions such as panic and headache after use, and may even cause increased blood pressure and increased heart rate, which can induce some potential heart diseases.

[0006] Bletilla striata polysaccharide is the main active ingredient of Bletilla striata. It is a neutral heteropolysaccharide obtained from Bletilla striata powder without water extraction and purification. It is also called Bletilla striata glue and Bletilla striata glucomannan. It is composed of a-mannose, 3-mannose and B-glucose bonded by 1→4 glycosidic bonds, and its molecular weight is between tens of thousands and hundreds of thousands of Da. Studies have shown that Bletilla striata polysaccharide has a variety of biological activities, including procoagulant, antibacterial, anti-inflammatory, antioxidant, anti-tumor, mucosal protection, and immunomodulation. The chemical structure of Bletilla striata polysaccharide has the characteristics of easy modification, low immunogenicity, biocompatibility, and biodegradability, but there are no reports on its application in submucosal injection in digestive endoscopic treatment. III. Summary of the invention

[0007] In view of the above situation, in order to solve the defects of the prior art, the purpose of the present invention is to provide a use of Bletilla striata polysaccharide in the preparation of submucosal injection solution for digestive endoscopic treatment, which can effectively solve the problem of short maintenance time of the existing submucosal injection solution when injected into the submucosal layer.

[0008] The technical solution solved by the present invention is the application of the Bletilla striata polysaccharide in the preparation of submucosal injection solution for digestive endoscopic treatment.

[0009] The preparation method of the polysaccharide of Bletilla striata is as follows: using 10 times the amount of distilled water to ultrasonically extract twice at 55°C, each time for 60 minutes, filtering, combining the filtrate, adjusting the pH of the filtrate to 6.5 with a 20% hydrochloric acid solution or a 20% sodium hydroxide solution, adding 3‰ (w / v) of medium-temperature a-amylase, hydrolyzing in a 60°C water bath for 3 hours, and then adjusting the pH to 7.5, and adjusting the substrate concentration to 4 mg·100 mL -1, add 3% (w / v) plant protease, stir and enzymolyze in a 45°C water bath for 3 hours, coarsely filter, ultrafilter with a 10,000 molecular weight ultrafiltration membrane, continue to reduce pressure and concentrate the filtrate to a thick paste, and then dry and crush in a vacuum drying oven to obtain the product.

[0010] A submucosal injection solution for digestive endoscopic treatment, the preparation method of which is as follows: 0.25-0.5g of Bletilla striata polysaccharide and 0.1g of methylene blue or indigo carmine are added into 40ml of normal saline to prepare the submucosal injection solution.

[0011] The Bletilla striata polysaccharide of the present invention has low cost, simple production process, and is easy to use under endoscopy. It can be added to a submucosal injection solution for use, maintain the submucosal layer bulge for a long time, is easy to operate, has a good use effect, and is highly practical. It is an innovation in submucosal injection solutions in digestive endoscopic treatment, and develops a new use of Bletilla striata polysaccharide. IV. Description of the drawings

[0012] Figure 1 It is the height of the protrusion of the injection of the present invention under the mucosa.

[0013] Figure 2 It is the remaining height of the injection of the present invention under the mucosa. V. Specific implementation methods

[0014] The specific implementation modes of the present invention are further described in detail below in conjunction with the accompanying drawings.

[0015] The present invention is the first to discover the use of Bletilla striata polysaccharide in the preparation of submucosal injections for digestive endoscopic treatment. The Bletilla striata polysaccharide powder prepared by the present invention is added to physiological saline to prepare a submucosal injection. Bletilla striata polysaccharide can also be purchased commercially and injected submucosally during EMR or ESD surgery, which can effectively increase the duration of the bulge, thereby improving the efficiency of endoscopic surgery. At the same time, the effects of low concentration and high concentration are not much different in a short period of time. Considering the dissolution rate and cost issues, it is clinically recommended to use low-concentration Bletilla striata polysaccharide for preparation. The relevant experimental data are as follows:

[0016] 1. Effect of Bletilla striata polysaccharide added to digestive endoscopy submucosal injection in pig stomach in vitro

[0017] 1. Grouping: Injection of low-concentration test group: 0.25g Bletilla striata polysaccharide + 0.1g methylene blue (for dyeing) + 40ml normal saline; Injection of high-concentration test group: 0.5g Bletilla striata polysaccharide + 0.1g methylene blue + 40ml normal saline; Injection of control group: 0.1g methylene blue + 40ml normal saline.

[0018] 2. Experimental process: 4 pig stomachs were isolated and the upper 1 / 3 was cut with tissue scissors. The specimens were fixed on a cork board.

[0019] Use a 5ml syringe and an endoscopic injection needle to inject 1ml of liquid into the gastric submucosal layer along the side. Inject three points, A, B, and C, on each piece, for a total of 12 injection points.

[0020] 3. Observation of mucosal elevation height: Use B-ultrasound probe to measure the mucosal elevation height at 0min, 5min, 10min, 15min, 20min, 30min, and 40min. After the measurement, cut the injection site to observe the separation of the mucosal layer and the muscularis propria.

[0021] 2. Test results

[0022] The test results showed that the maintenance time of the low-concentration group and the high-concentration group was significantly longer than that of the control group, and the diffusion time was significantly slower. Figure 1 As shown in Figure 2, there was no significant difference in the remaining height maintenance time between the low-concentration group and the high-concentration group within 40 minutes. Figure 2 shown.

[0023] Conclusion

[0024] The present invention adds Bletilla striata polysaccharide to the submucosal injection solution, which can effectively increase the time of maintaining the protrusion, thereby improving the efficiency of endoscopic surgery. At the same time, the effects of low concentration and high concentration are not much different in a short time. Considering the problems of dissolution rate and cost, it is clinically recommended to use low-concentration Bletilla striata polysaccharide for preparation. The operation is simple, the use effect is good, and the practicability is strong. It is an innovation in the submucosal injection solution in digestive endoscopic treatment, and a new use of Bletilla striata polysaccharide is developed.

[0025] It should be pointed out that the above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Any technician familiar with the profession can make changes or modify the technical contents disclosed above into equivalent embodiments with equivalent changes without departing from the scope of the technical solution of the present invention, which all fall within the protection scope of the present invention.

Claims

1. Application of Bletilla striata polysaccharide in the preparation of submucosal injection solution for digestive endoscopic treatment.

2. The use of the Bletilla striata polysaccharide according to claim 1 in preparing a submucosal injection for digestive endoscopic treatment, characterized in that: The preparation method of the Bletilla striata polysaccharide is as follows: using 10 times the amount of distilled water, ultrasonically extracting twice at 55°C for 60 minutes each time, filtering, combining the filtrates, adjusting the pH of the filtrates to 6.5 with a 20% hydrochloric acid solution or a 20% sodium hydroxide solution, adding 3‰ mesophilic α-amylase, hydrolyzing in a 60°C water bath for 3 hours, and then adjusting the pH to 7.

5. The substrate concentration is adjusted to 4 mg·100 mL -1 , add 3% plant protease, stir and enzymolyze in a 45°C water bath for 3 hours, coarsely filter, ultrafilter with a 10,000 molecular weight ultrafiltration membrane, continue to reduce pressure and concentrate the filtrate to a thick paste, and then dry and crush in a vacuum drying oven to obtain the product.

3. A submucosal injection for digestive endoscopic treatment, characterized in that: Add 0.25-0.5g of Bletilla striata polysaccharide and 0.1g of methylene blue or indigo carmine into 40ml of normal saline to obtain the product.